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Abstract
Upregulation and activation of developmental axon guidance molecules, such as semaphorins and members of the Eph
receptor tyrosine kinase family and their ligands, the ephrins, play a role in the inhibition of axonal regeneration following
injury to the central nervous system. Previously we have demonstrated in a knockout model that axonal regeneration
following spinal cord injury is promoted in the absence of the axon guidance protein EphA4. Antagonism of EphA4 was
therefore proposed as a potential therapy to promote recovery from spinal cord injury. To further assess this potential, two
soluble recombinant blockers of EphA4, unclustered ephrin-A5-Fc and EphA4-Fc, were examined for their ability to promote
axonal regeneration and to improve functional outcome following spinal cord hemisection in wildtype mice. A 2-week
administration of either of these blockers following spinal cord injury was sufficient to promote substantial axonal
regeneration and functional recovery by 5 weeks following injury. Both inhibitors produced a moderate reduction in
astrocytic gliosis, indicating that much of the effect of the blockers may be due to promotion of axon growth. These studies
provide definitive evidence that soluble inhibitors of EphA4 function offer considerable therapeutic potential for the
treatment of spinal cord injury and may have broader potential for the treatment of other central nervous system injuries.
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Introduction
In addition to inhibitory molecules associated with myelin and
astrocytes, including Nogo, myelin-associated glycoprotein and
chondroitin sulfate proteoglycans [1,2,3,4,5,6], upregulation of
developmental axon guidance molecules, such as semaphorins and
members of the Eph receptor tyrosine kinase family, have been
shown to play a role in inhibition of axonal regeneration following
central nervous system injury [7,8,9,10]. EphA4 expression is
upregulated following spinal cord injury [11,12,13] and EphA4
null mice show substantially decreased astrocytic gliosis, concom-
itant with extensive axonal regeneration and recovery of function
[12].
Based on the null mouse results, we postulated that blockade of
EphA4 function could promote repair following spinal cord injury
in wildtype mice. Eph receptors and their ephrin ligands are
membrane bound, and activation of the receptor requires
clustering within the cell membrane [14]. Artificial Eph receptor
activation is achieved by stimulating with soluble ephrin-
immunoglobulin Fc fusion proteins that have been clustered
together using anti-Fc antibodies [15,16]. Clustered ephrin-A5-Fc
promotes EphA4 phosphorylation and downstream signaling in
astrocytes and in neurons, inhibiting neurite outgrowth [12,17].
Conversely, if the ephrin-Fc or Eph-Fc proteins are unclustered,
they antagonize Eph:ephrin interactions [15,16,18], resulting in
enhanced neurite outgrowth when neurons are grown in the
presence of EphA4 [7,19].
In the current study, we investigated whether inhibition of
EphA4 in vivo is of therapeutic benefit following spinal cord injury.
Two different blockers of EphA4 were examined for their ability to
promote axonal regeneration and improve functional outcome
following spinal cord hemisection in wildtype mice. These were
soluble unclustered ephrin-A5-Fc and soluble unclustered EphA4-
Fc. Ephrin-A5-Fc potentially saturates both endogenous EphA4,
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partners, EphA3, EphA5, EphA6 and EphA7 [20]. We have
previously shown that ephrin-A5-Fc can block EphA4 activation
and hence inhibition of neurite outgrowth [12]. Conversely,
soluble EphA4 receptor (EphA4-Fc) can bind to both A- and B-
type ephrin ligands [21]. By competitively binding to endogenous
ephrin ligands, EphA4-Fc prevents ephrin-induced cell-bound
EphA4 activation [22]. Due to the promiscuous nature of EphA4,
which interacts with almost all of the ephrin ligands, we
hypothesized that EphA4-Fc would be the more effective EphA4
blocking agent in vivo. Administration of either ephrin-A5-Fc or
EphA4-Fc to wildtype mice for 2 weeks following spinal cord
injury resulted in substantial axonal regeneration and functional
improvement, indicating that blocking of EphA4 interactions is a
viable therapeutic option for the treatment of spinal cord injury.
Results
Soluble unclustered ephrin-A5-Fc and EphA4-Fc both
block EphA4 activation in vitro
We have previously shown that astrocytes in culture express
EphA4 and that the EphA4 is phosphorylated by addition of
clustered ephrin-A5-Fc or a number of inflammatory cytokines,
including interferon gamma (IFNc) [12]. In this study, we
therefore first demonstrated that basal EphA4 phosphorylation
was blocked by the addition of unclustered ephrin-A5-Fc to the
astrocyte cultures, in contrast to clustered ephrin-A5-Fc that has
previously been shown to promote EphA4 phosphorylation
(Fig. 1a). To test the effectiveness of unclustered ephrin-A5-Fc at
inhibiting increased levels of EphA4 phosphorylation we used
IFNc rather than clustered ephrin-A5-Fc, to increase EphA4
phosphorylation. This was to prevent possible unbound anti-
human Fc antibodies, present in the clustered ephrin-A5-Fc, from
clustering the blocker and making it become an EphA4 activator
instead. Addition of unclustered ephrin-A5-Fc inhibited the
interferon-induced increase in EphA4 phosphorylation (Fig. 1a).
To test the ability of EphA4-Fc to act as a blocker, we cultured
embryonic day 16 cortical neurons, which express ephrins, on the
EphA4-expressing astrocytes. Similar to what we have previously
shown for ephrin-A5-Fc [12], addition of unclustered EphA4-
Fc promoted dose-dependent neurite outgrowth (p,0.001,
F4,1810=25) (Fig. 1b, c). Therefore, both the soluble EphA4
ligand (ephrin-A5-Fc) and the soluble EphA4 receptor (EphA4-Fc)
are able to block EphA4 activation in vitro.
Soluble unclustered ephrin-A5-Fc and EphA4-Fc both
diminish astrocytic gliosis
As the physical barrier imposed by the development of the
gliotic scar is known to impede axonal regeneration following
spinal cord injury, we examined the effect of the EphA4 blockers
on astrocytic gliosis. We analyzed glial fibrillary acidic protein
(GFAP) expression by immunohistochemistry at 4 days after the
injury, following a 3-day treatment, to assess early effects on gliosis.
Although all animals showed a strong astrocytic response, mice
treated with EphA4-Fc or ephrin-A5-Fc showed a significant, but
modest, decrease in GFAP positive astrocyte numbers (p,0.001,
F2,127=47.27) and these astrocytes had fewer GFAP-positive
Figure 1. Unclustered ephrin-A5-Fc and EphA4-Fc promote neurite outgrowth. (A) Immunoprecipitation (IP) of phosphotyrosine
containing proteins using anti-pY100 antibody followed by immunoblot (IB) for EphA4 showed that unclustered ephrin-A5-Fc (uncl-A5) inhibits basal
and IFNc-induced EphA4 receptor phosphorylation in cultured astrocytes, whereas clustered ephrin-A5-Fc (cl-A5) upregulates EphA4 receptor
phosphorylation. (B–C) Inhibition of neurite outgrowth on astrocytes was blocked in a dose-dependent manner by addition of unclustered EphA4-Fc;
10 mg/ml of EphA4-Fc and ephrin-A5-Fc were used in (C). Results in B show mean6SEM, ***p,0.001, using one-way ANOVA with Tukey’s multiple
comparison test, from n$100 neurons per condition, representative of n=3 experiments. Scale bar in C, 100 mm.
doi:10.1371/journal.pone.0024636.g001
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(p,0.001, F2,9=49.27) compared to controls (Fig. 2a–c). Astro-
cytic gliosis was still prominent as assessed by GFAP expression at
2 weeks after injury and following 2 weeks of ephrin-A5-Fc
treatment (Fig. 3). However, immunostaining for EphA4 showed
that, unlike in control mice, there was a marked reduction in
EphA4 immunostaining surrounding the injury site, which was not
observed further away from the injury site or on the contralateral
side (Fig. 3). Immunostaining for the glial scar marker chondroitin
sulfate proteoglycan (CSPG) also appeared to be diminished in the
treated spinal cords (Fig. 3).
Soluble unclustered ephrin-A5-Fc and EphA4-Fc both
promote regeneration by 6 weeks in vivo
Having demonstrated the activity of the EphA4 blockers on the
gliotic response, we next investigated their effect on axonal
regeneration in the wildtype mice. Anterograde tracing was used
to compare the effectiveness of a 1-week versus a 2-week treatment
on axonal regeneration at 2 and 6 weeks after the injury. No axons
were observed distal to the lesion site 2 weeks after injury in any
condition (Fig. 4). Animals that were treated for 1 week with
ephrin-A5-Fc displayed increased numbers of axons approaching
the lesion site at 2 weeks, compared to controls (Fig. 4a, b, c). The
axons in the treated mice also had tip morphology suggestive of
robust growth cones, indicating that inhibition of Eph/ephrin
signaling reduced growth cone collapse (Fig. 4b9). No further
improvement was observed at 6 weeks after injury, in control
(Fig. 5a, Fig. S1a) or ephrin-A5-Fc treated mice (Fig. 5b). No axons
were observed entering or crossing the lesion site at 6 weeks after
injury, although more axons reached the proximal lesion edge of
the injury in treated animals compared to controls (Fig. 5e;
p,0.001, F3,21=12.61 at 100 mm proximal to the lesion site and
p,0.001, F3,21=15.97 at 750 mm).
As treatment for 1 week was not effective at promoting axonal
regeneration, we extended the delivery period to 2 weeks to
determine whether longer administration of ephrin-A5-Fc or
EphA4-Fc would be more effective. We initially examined axonal
regeneration immediately after the 2-week delivery period and
observed that treatment with ephrin-A5-Fc resulted in increased
numbers of axons proximal to the lesion site (Fig. 4c, d; p,0.001,
F2,12=24.51 for 100 mm proximal to the lesion and p,0.001,
F2,12=44.05 for 750 mm). In addition, a small proportion of axons
entered but did not cross the injury site (Fig. 4d9). A similar result
was found following a 2-week treatment with EphA4-Fc.
Anterograde tracing revealed that most mice in the treated group
had axons bordering or within the lesion site (Fig. 4e, f).
Importantly, at 6 weeks after the injury, we observed that
administration of ephrin-A5-Fc or EphA4-Fc over 2 weeks resulted
in substantial axonal regeneration, with many axons entering and
crossing the lesion site to extend distally in both treatment groups
(p,0.001, F15,81=25.12; Fig. 5c–e, Fig. S1b,c). To determine if greater
regeneration resulted from local administration compared to systemic
administration, EphA4-Fc was applied in gelfoam above the lesion site.
This resulted in slightly better axonal regeneration than the 1-week
intraperitoneal (i.p.) treatment, with many axons entering the lesion site
(Fig. S1d). However, as this regimen was not as effective as the 2 week
i.p. treatment, it was not pursued further in the current study.
T h ep r e s e n c eo fa x o n sa d j a c e n tt ot h ei n j u r ys i t ea t2w e e k si n
treated mice couldbe due to a lackof axonal die-back or regeneration
of axons after die-back. To determine which of these was occurring,
cortical axons were anterogradely labeled with Fluoro-ruby 1 week
prior to injury. After spinal cord hemisection, EphA4-Fc was
administered for 3 days and tissue was taken for analysis at 4 days,
a time at which axonal die-back should occur. Compared to the
number of labeled axons 1.5 mm from the injury site, at 1 mm
control mice (n=3) had 9365.5% and EphA4-Fc-treated mice
(n=5) had 9766.6% the number of axons,whereas at 0.5 mm,there
Figure 2. Unclustered ephrin-A5-Fc and EphA4-Fc partially reduce astrocytic gliosis. (A–C) Immunohistochemical analysis of GFAP
expression 4 days after spinal cord hemisection and following 3 days administration of Fc fusion protein indicated that, (A) compared to PBS
treatment (n=6), ephrin-A5-Fc (n=3) and EphA4-Fc (n=3) treatment decreased astrocytic gliosis. There were significant decreases in the number of
astrocytes (B) and GFAP density at the lesion site was reduced following ephrin-A5-Fc or EphA4-Fc treatment (C). Results in B and C show mean6SEM,
**p,0.01, ***p,0.001, using one-way ANOVA with Tukey’s multiple comparison test. Scale bar in A, 100 mm.
doi:10.1371/journal.pone.0024636.g002
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axons in treated animals (74613.1% in the EphA4-Fc-treated group
(n=5),comparedto5466.1% in controls (n=3)p=0.22, t-test) (Fig.
S2). This suggests that EphA4-Fc treatment did not prevent axonal
die-back but rather promoted axon regrowth.
Soluble unclustered ephrin-A5-Fc and EphA4-Fc both
promote functional recovery
Mice were assessed for functional recovery, as determined by the
use of their left hind limb, at 5 weeks, immediately prior to the
injection of anterograde tracer. Both ephrin-A5-Fc and EphA4-Fc
treatments resulted in a significant improvement in the ability to
walk (p,0.001, F3,18=20.04) or climb (p,0.001, F3,18=35.87) on a
grid, with animals making far fewer foot falls and showing weight
support with the affected left hind limb (Fig. 6a; Videos S1 and S2).
Mice treated with EphA4-Fc also showed significant improvement
of function based on the mouse modified open-field behavior test
(mBBB scale; [23], (Fig. 6b; repeated measures ANOVA, p,0.001,
F3,15=92.27) and grasp ability (PBS-treated mice scored 1.160.8,
indicating partial movement of the paw, with no movement of the
Figure 3. EphA4 immunostaining is decreased adjacent to injury site in ephrin-A5-Fc treated mice. Immunohistochemical analysis of
(A,B) GFAP, (C–F) EphA4 and (G,H) CSPG expression at 2 weeks after spinal cord hemisection and 2 weeks of ephrin-A5-Fc treatment indicated that
there was robust GFAP staining in both treated and control mice (A,B). However, in treated mice ipsilateral astrocytes adjacent to the injury site had
markedly decreased EphA4 staining (C–F). There was also moderately decreased CSPG staining adjacent to the injury site of treated mice (G,H).
Arrows indicate lesion site. Scale bars in A–D, G,H, 100 mm; E,F, 50 mm.
doi:10.1371/journal.pone.0024636.g003
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grasp and slight movement of toes and paw).
Kinematic gait analysis indicated that the treated mice had a more
normal looking step cycle pattern, with an obvious swing phase of the
paretic hind limb (Fig. 6c–f, Videos S3 and S4). Individual joint
movement was analyzed by measurement of joint angle throughout
one step cycle in the EphA4-Fc-treated mice compared to untreated
mice and intact controls. In treated mice, the hip joint started to
Figure 4. Axonal regrowth towards the lesion site in ephrin-A5-Fc-treated spinal cords 2 weeks after injury. A montage of confocal
images 2 weeks after injury from representative sections anterogradely traced with Fluoro-ruby showing that (A) PBS-treated mice had few labeled
axons rostral to the lesion site and that (B) one week of ephrin-A5-Fc treatment increased the number of axons proximal to the lesion site. Axons in
the ephrin-A5-Fc-treated mice had robust growth cones. Boxes show enlarged regions in a9 and b9. Scale bars for A, B, A9,B 9,5 0mm. Dotted lines in A,
B indicate the border of the lesion site and the right hand side of panels is caudal to the lesion site (C) Axonal regrowth was determined by semi-
quantitative analysis of axons 100 mm or 750 mm rostral to the lesion site after ephrin-A5-Fc (A5) treatment for 1 week (1 W) or 2 weeks (2 W): ordinal
scale 0=no axons; 1=fewer than 10 axons; 2=10–50 axons; 3=more than 50 axons per section (from n$5 sections per spinal cord). *p,0.05,
**p,0.01, ***p,0.001 compared to the PBS-treated control, using one-way ANOVA with Tukey’s multiple comparison test. (D) Two weeks treatment
with ephrin-A5-Fc promoted substantial axonal regeneration into the lesion site; box enlarged in D9. Scale bars D, D9,5 0mm. (E) Regrowth of labeled
corticospinal tract axons towards the lesion site at 2 weeks, after 2 weeks EphA4-Fc treatment, with distance from center of injury site; *p,0.05. (F)
Representative images of labeled corticospinal tract axons 2 weeks after injury, and a 2-week treatment protocol, showing distance to the center of
the injury site.
doi:10.1371/journal.pone.0024636.g004
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(Fig. 6g). The knee joint showed some movement but the timing was
altered, with a shorter stance phase (Fig. 6h), whereas untreated mice
showed almost no knee movement. Movement of the ankle joint of
treated mice was small. However, in untreated mice the effect at the
ankle was very variable, ranging from fully flexed (spastic) to dragging
(Fig. 6i).
Prolonged therapeutic delivery and extended recovery
following EphA4-Fc treatment
As EphA4-Fc was at least as effective as ephrin-A5-Fc at
promoting recovery from spinal cord injury, but with half the
number of doses, it was chosen for further analysis. To determine
whether more prolonged administration would further enhance
recovery, EphA4-Fc was administered for either 2 or 4 weeks and
Figure 5. Axonal regeneration in ephrin-A5-Fc- and EphA4-Fc-treated spinal cords 6 weeks after injury. A montage of confocal images,
6 weeks after injury, from representative sections anterogradely traced with Fluoro-ruby showing that (A) PBS-treated mice had few labeled axons
rostral to the lesion site. (B) One week of EphA4-Fc treatment increased the number of axons rostral to the lesion site but did not promote
regeneration through it. A 2-week treatment with ephrin-A5-Fc (C) or EphA4-Fc (D) was sufficient to promote regeneration through and caudal to the
lesion site. Scale bars for A–D, 50 mm. Arrows point to center of lesion site. (E) Axonal regrowth was determined by semi-quantitative analysis of
labeled axons rostral and caudal to the lesion site after ephrin-A5-Fc (A5) or EphA4-Fc (A4) treatment for 1 week (1 W) or 2 weeks (2 W): ordinal scale
0=no axons; 1=fewer than 10 axons; 2=10–50 axons; 3=more than 50 axons per section (from n$5 sections per spinal cord). *p,0.05, ***p,0.001
compared to PBS control, using one-way ANOVA with Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0024636.g005
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and grid climbing accuracy were improved by EphA4-Fc
treatment compared to controls, but there was no significant
difference between animals receiving treatment over 2 or 4 weeks.
(Fig. 7a,b). To determine whether recovery for longer than 6 weeks
would result in further functional improvement, EphA4-Fc was
administered for 2 weeks and grasp score and grid climbing
accuracy assessed at 8, 12 and 24 weeks post injury. Both grasp
score and grid climbing accuracy reached a plateau between 8 and
12 weeks following injury (Fig. 7c, d). These data suggests that a
Figure 6. Ephrin-A5-Fc- or EphA4-Fc-treated mice show significant functional recovery 5 weeks after spinal cord injury. (A) Walking
and climbing on a grid were significantly improved following 2 weeks treatment with ephrin-A5-Fc (A5-2W) or EphA4-Fc (A4-2W). One week of
ephrin-A5-Fc (A5-1W) treatment resulted in significant improvement in grid walking but not in climbing as assessed by ANOVA, although it was
significant by t-test (mean6SEM, *p,0.05, ***p,0.001 using one-way ANOVA with Tukey’s comparison analysis; #p,0.05 using t-test). (B) The mBBB
score was measured up to 5 weeks after spinal cord injury (SCI) in PBS- (n=7) and EphA4-Fc- (A4-Fc) (n=6) treated mice. Results show mean6SEM
(***p,0.001 comparing treatment groups at the indicated time point using one-way ANOVA with Tukey’s multiple comparison test). Kinematics of
the left hind limb were analyzed from videotapes of locomotion of mice on the treadmill with reflective markers on the iliac crest, hip joint, knee joint
and ankle joints. (C–F) Stick figures of the angles between each joint were used to depict one complete step cycle, with the beginning of the swing
phase marked with an arrow for the push off point (PO) of the left hind limb and the pattern obtained for a normal intact mouse at a treadmill speed
of 12 m/min (C). Panels (D–F) show a representative pattern for one mouse from each of the PBS (n=7), ephrin-A5-Fc (A5-Fc) (n=2) and EphA4-Fc
(A4-Fc) (n=6) groups of mice 5 weeks after spinal cord injury, at a treadmill speed of 12 m/min. Treatment over 2 weeks with ephrin-A5-Fc and
EphA4-Fc resulted in approximation of the movement pattern seen in intact animals, including a phase of lifting the paw off the surface. (G–I)
Average kinematic profile combined from profiles of EphA4-Fc-treated mice (n=6), of joint angle changes over one complete step cycle of the left
hip (G), knee (H) and ankle joints (I) 5 weeks after spinal cord injury in PBS- and EphA4-Fc-treated mice compared to the intact mouse pattern. The
point of push off (PO) and the beginning of the swing phase is indicated by a black vertical line through the graph. Results are expressed as
mean6SD.
doi:10.1371/journal.pone.0024636.g006
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improvement and that functional improvement observed by 8
weeks is maximal.
Discussion
The results of the present study have revealed that, following
spinal cord hemisection in wildtype mice, a 1-week treatment with
an EphA4 blocker was largely ineffective, enhancing axonal
regrowth to, but not beyond, the injury site. However, 2 weeks
administration of either ephrin-A5-Fc or EphA4-Fc promoted
extensive axonal regeneration by 6 weeks, as well as significant
behavioral improvement. Although the observed level of improve-
ment was similar with both treatments, the same outcome was
achieved using fewer treatments and a lower dose of EphA4-Fc
than for ephrin-A5-Fc. This may reflect the promiscuous affinities
of EphA4, which is the only A class receptor that binds with high
affinity to multiple A and B type ephrins [24,25]. This then allows
EphA4-Fc to block multiple Eph:ephrin interactions [21].
The 1-week treatment protocol was sufficient to increase the
number of axons regrowing to the lesion site. This is likely to lead
to enhanced function at least to the hip joint, an outcome that was
reflected in improvement on the relatively simple horizontal grid
test. However, it was not enough to produce significant
improvement in the more difficult climbing task, which also
requires the ability to lift the leg more precisely, as well as to bear
weight. Using the same mouse model of left spinal hemisection, a
similar improvement in function, with concomitant regrowth to,
but not into or beyond the injury site, was found in response to
forced treadmill exercise [26].
Interestingly, a 4-week treatment of EphA4-Fc was no more
effective than a 2-week treatment. This may be due to permeability
of the blood-brain barrier. Eph:ephrin signaling regulates angio-
genesis [27] and blood vessel structure [28,29], including in the
nervous system [30]. We have previously demonstrated that, unlike
wildtype mice in which the blood-brain barrier has substantially
repaired by 1 week, the blood-brain barrier at the injury site in
EphA4 null animals still displays extensive leakage at 2 weeks, with
substantial repair only becoming apparent by 3 weeks [30].
Treatment with Eph blockers may thus have extended blood-brain
barrier permeability in the wildtype mice, to the point where it
allowed the blockers to enter the injury site for 2 weeks, but
precluded subsequent access due to barrier repair. This may be due
to direct effects on the endothelial cells, as well as on astrocytes that
contribute to blood-brain barrier formation [31].
A further, as yet unexplored mechanism which may contribute
to the regeneration and recovery promoted by blocking of EphA4
is an effect on inflammation. EphA4 null mice show thymic
alterations and T cell defects [32]. Given that blocking of
inflammation has also been demonstrated to promote recovery
from spinal cord injury [33,34], it is possible that blocking of
EphA4 altered the inflammatory response following injury.
It is interesting to note that the regrowing axons in the treated
mice were generally long and relatively straight in appearance,
although there was also substantial collateral sprouting and some
deviation around the most damaged parts of the injury site. Axons
regenerating in response to other factors generally do not follow
such a straight line [35]. As EphA4 is upregulated on astrocytes
following injury, we hypothesize that its expression may modulate
axon:astrocyte interactions.
Figure 7. Prolonged treatment with EphA4-Fc and extended recovery. (A, B) To determine whether extending treatment length to 4 weeks
promoted greater functional improvement EphA4-Fc was administered for 2 weeks or 4 weeks, after which (A) grasp score and (B) grid climbing
accuracy were assessed at 6 weeks post-injury. Both the 2-week and 4-week treatments improved functional outcomes compared to controls, but
were not significantly different to each other. (C, D). To determine whether extending the recovery period for longer than 6 weeks would allow
further functional improvement, animals were treated with EphA4-Fc for 2 weeks after injury and assessed at 8, 12 and 24 weeks. Analysis of (C) grasp
score and (D) grid climbing accuracy showed that no further improvements were observed after 8 weeks in control or treated mice. (mean6SEM,
*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0024636.g007
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promoted regeneration appears to be primarily at the level of
the axonal growth cone, blocking EphA4:ephrin interactions that
would normally result in growth cone collapse. Given the
bidirectional signaling that occurs for Eph:ephrin interactions
[36], an ephrin expressed on the axonal growth cone may induce
growth cone collapse in response to EphA4 expression on the
astrocytes. In addition, EphA4 expressed on the growth cone may
also induce growth cone collapse in response to ephrins expressed
on astrocytes [37] or myelin [38].
We have previously reported a strong decrease in astrocytic
activation and proliferation in EphA4 null mice (generated by
homologous recombination) following a lateral hemisection injury
[12]. However, similar to previous reports using other EphA4
antagonists after spinal cord injury, we show here that astrocytic
gliosis, as defined by GFAP expression, is not robustly affected
[39,40]. This is similar to a recent examination of a dorsal
hemisection injury in EphA4 null mice generated using gene trap
methodology, which did not show an effect on gliosis [41]. Recent
in vitro experiments showed that effects of EphA4 on GFAP
expression in cultured astrocytes were relatively modest, while
effects on the astrocyte actin cytoskeleton and focal adhesion were
more pronounced [42]. Therefore, while the effect of EphA4 on
GFAP expression requires further elucidation, it is clear that
regulation of EphA4 activity modulates broader astrocyte
reactivity. In the current study, the difference in level of GFAP
expression was modest but significant and may reflect the
substantial biological activity of EphA4-Fc delivered repeatedly
compared to small peptide or antisense approaches. In particular,
our results suggest that, even in the presence of gliosis as defined
by upregulation of GFAP expression, functional recovery and
axonal regeneration can still occur. Of note, immunostaining for
EphA4 was decreased adjacent to the injury site in treated spinal
cords, which indicates that a major repulsive signal on the surface
of the reactive astrocytes was diminished in the treated animals
close to the site of injury and may account for the ability of axons
to cross and extend past the injury site.
Functional blocking using soluble ligands or receptors appears
to be required as partial downregulation of EphA4 expression
using antisense oligonucleotides has proven ineffective at promot-
ing regeneration following spinal cord injury [43]. Furthermore,
use of an EphA4 peptide antagonist [44] following spinal cord
injury was only partially effective [39]. The ability of the two
different Fc fusion proteins used in the present study to physically
block interactions between multiple Eph receptors and ephrin
ligands may also be an important part of their mechanism of
action and allow for wider inhibition than the more constrained
peptides.
One of the mechanisms downstream of Eph receptor activation
leading to growth cone collapse is likely to involve the Rho/Rac/
Cdc42 cellular apparatus, with Rho-GTPase inhibition previously
shown to promote recovery from spinal cord injury [45,46,47].
Rho is activated downstream of repulsive guidance molecules and
inhibits axonal regeneration through the stimulation of growth
cone collapse [46,48,49]. The equilibrium between Rho, Rac and
Cdc42 is shifted towards Rho activation following ephrin
activation of EphA4 and causes growth cone collapse [50].
Blocking Rho alters the bias towards Rac and Cdc42 activity,
promoting axonal outgrowth [50,51,52]. However, the reported
functional recovery after injury following direct Rho inhibition by
use of Rho pathway inhibitors occurs within 1–2 days after injury
[45], which is earlier than the recovery we observe with EphA4
antagonism. This suggests that directly inhibiting Rho may affect
other cellular processes, such as decreasing apoptosis [46]. Future
experiments will assess whether Rho activation is diminished in
spinal cords after treatment with the Fc fusion protein blockers.
Expression of a number of other developmental repulsive axon
guidance molecules has also been shown to be upregulated
following spinal cord injury, with semaphorins in particular
appearing to have an effect similar to that observed for EphA4
[8,9,53,54]. Blocking of Wnt-5a-Ryk signaling also promotes
axonal regrowth in the corticospinal tract and enhances functional
recovery [55]. Blocking of EphA4 is highly effective at promoting
regeneration of multiple axonal tracts, most likely due to its high
promiscuity in binding to all ephrins and the widespread
expression of EphA4 and different ephrin ligands on a wide range
of neurons, as well as astrocytes, myelin, meningeal and
endothelial cells [7]. However, a combined therapy that includes
blocking of semaphorins, for example, may be even more effective
at promoting axonal regeneration and further functional recovery.
In summary, the effectiveness of both ephrin-A5-Fc and EphA4-
Fc treatments provides the first definitive evidence that soluble
inhibitors of EphA4 function can be used therapeutically to
promote recovery from spinal cord injury. Not only do these
inhibitors hold promise for treatment of spinal cord injury, but also
they are likely to promote recovery following brain trauma or
stroke.
Materials and Methods
Protein expression and purification
To produce the Fc fusion proteins, the extracellular domains of
mouse EphA4 (amino acids 1–546 of NP_031962.2) and human
ephrin-A5 (amino acids 1–201 of NP_001953.1) were cloned into
the pTIgBOS vector [56]. These constructs were used to stably
transfect the Chinese hamster ovary (CHO) cell line (ATCC, USA)
to produce EphA4-Fc and ephrin-A5-Fc respectively. High
producer lines were selected and routinely grown in GIBCO
Hybridoma serum-free medium (Invitrogen). The fusion protein
was purified from cell culture supernatants by Protein A Sepharose
(Amersham Biosciences) affinity chromatography. Purity was
assessed by SDS-PAGE and determined to be .95% for
EphA4-Fc and .75% for ephrin-A5-Fc.
Astrocyte and neuronal cultures and neurite length
measurement
For analysis of EphA4 phosphorylation, clustered and unclus-
tered ephrin-A5-Fc (1.5 mg/ml and 10 mg/ml respectively) was
added to monolayers of primary astrocytes (cultured from
postnatal day 1–3 cortices) for 1 hour. To induce EphA4
phosphorylation in the absence of added clustered ephrin-A5-Fc,
IFNc (100 U/ml, BD Biosciences, Sydney, Australia) was then
added to the astrocytes for 1 hour. Phosphoproteins were
immunoprecipitated and EphA4 levels quantified as previously
described [12]. For analysis of neurite length, embryonic day 16
cortical neurons were plated at 5,000 cells/well in chamber slides
(Falcon; BD Biosciences) on confluent monolayers of astrocytes
pretreated for 1 hour with unclustered ephrin-A5-Fc (10 mg/ml)
or unclustered EphA4-Fc (0 mg/ml, 1 mg/ml, 10 mg/ml or
100 mg/ml). After 2 days, cells were fixed and immunostained
for the neuronal marker bIII-tubulin (1:2000, Promega). Images of
neurites were digitally captured using a Zeiss Axioplan 2 imaging
fluorescence microscope, fitted with a Zeiss Axiocam HRc digital
camera and Zeiss Axiovision Release 4.5 software. Neurite length
was measured by HCA-Vision software (Neurite Analysis Module
V1.0.1, CSIRO Mathematical and Information Sciences, Sydney,
Australia). The data were analyzed by one-way ANOVA followed
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Ethics statement
All procedures were approved by the University of Melbourne
(approval #0706768) or the University of Queensland (approval
#SBMS/466/08) Animal Ethics Committee in accordance with
the Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes.
Animals and surgical procedures
Spinal cord injury surgeries were performed on adult (8–12
week old) male C57BL/6 mice. Mice were anesthetized with a
mixture of ketamine and xylazine (100 mg/kg and 10 mg/kg,
respectively), after which they received a complete left hemisection
at vertebral level T12 as previously described [12]. Briefly, after
laminectomy, a left hemisection was made at T12 with a fine
ophthalmic blade, after which the overlying muscle and skin were
sutured. The mice were randomly assigned to the control
(phosphate-buffered saline; PBS), unclustered ephrin-A5-Fc or
unclustered EphA4-Fc groups prior to recovery from the
anesthetic and were analyzed at various time points up to 24
weeks post-injury. Administration of the PBS, ephrin-A5-Fc or
EphA4-Fc by i.p. injection began 2 hours following surgery. To
ensure competitive saturation of endogenous Eph receptor or
ephrin ligands, high doses of EphA4-Fc and ephrin-A5-Fc were
used. Ephrin-A5-Fc has a relatively quick clearance rate [57] and
in preliminary experiments was injected daily for 3 days, 1 week or
2 weeks at quantities that would surpass 250 nM (680 mg/dose) at
dosing. Analysis of EphA4-Fc clearance showed sustained levels
with slower clearance and serum concentrations sufficient for
saturation (.50 nM) after 48 hours with doses of 1 mg (Fig. S1).
To account for this, EphA4-Fc was injected as a larger initial dose
(1 mg) at 2 hours, followed by a lower dose (500 mg) every second
day for 3 days, 2 weeks or 4 weeks. Administration of these Fc
fusion proteins was well tolerated by the mice. All treated animals
appeared healthy and active and unaffected by the amount of
protein injected.
Tetramethylrhodamine- or fluoroscein-conjugated dextrans
(Fluoro-ruby and Fluoro-emerald, respectively; Invitrogen) were
used as anterograde tracers to examine the extent of regeneration
of lesioned lateral white matter tract axons or corticospinal tract
axons. Tracing was performed after behavioral analyses and 1
week prior to tissue collection. For lateral white matter tract axons,
the mice were anesthetized and the spinal cord was exposed in the
cervical region as described above. The tracer was injected into
the spinal cord at the level of the cervical enlargement, ipsilateral
to the lesion (three injection points, 0.3 ml at 50 mg/ml each) and
left for another 7 days as described previously [12]. For the axon
die-back analysis, lateral white matter tract tracing was performed
1 week prior to spinal cord hemisection, as described above. Mice
were allowed to recover for 7 days before undergoing a lateral
hemisection injury and treatment with EphA4-Fc as described.
Mice were sacrificed 4 days after spinal cord injury for analysis.
Immunohistochemistry and astrocyte counts
Standard immunohistochemical procedures, using rabbit anti-
glial fibrillary acidic protein (GFAP; 1:500, Dako), mouse anti-
CSPG (1:200; Sigma) or rabbit anti-EphA4 (F88 antiserum,
prepared in Bartlett laboratory against a peptide corresponding to
amino acids 938–953 of the intracellular SAM domain of EphA4
(GenBank accession number NM007936)) were performed on
longitudinal sections of spinal cord at either 4 days or 2 weeks after
injury, following a 3-day or 2-week treatment respectively. The
total number of GFAP-expressing astrocytes at 4 days was counted
in a 0.25 mm
2 grid at the lesion site, in every third serial
longitudinal 10 mm section. Only astrocytes in which the nucleus
was present in the section were included in the cell density counts.
GFAP density was measured at 61000 magnification using Image
J software (Wayne Rasband, National Institutes of Health). The
GFAP density was averaged from at least five boxes per section
and five sections per spinal cord, with the results being presented
as the percentage of each field showing GFAP expression.
Analyses of anterograde tracing
Longitudinal serial sections for analysis of anterograde tracing
were cut on a freezing microtome at 75 mm and then examined
using fluorescence and confocal microscopy. The number of axons
reaching the lesion site was counted in the area at the edge of the
lesion site (100 mm) and 750 mm proximal to the lesion site under
6400 magnification, from at least five sections per spinal cord.
Completeness of the hemisections was confirmed by examination
of hematoxylin and eosin (H&E) or GFAP-labeled sections. To
determine the extent of regrowth past the lesion site, the
percentage of mice in which axons crossed the lesion site and
were present 100 mm, 1 mm, 2.5 mm or 5 mm distal to the lesion
site was determined. Comparison of the average number of
labeled axons per section between the groups was performed using
one-way ANOVA. Images of traced lateral white matter tract
axons were obtained from Z-stacks generated by confocal
microscopy, using a Bio-Rad MRC1024 confocal scanning laser
system installed on a Zeiss Axioplan 2 microscope and Confocal
Assistant version 4.02 software. For the axon die-back analysis, the
total number of axons observed at 0.5 mm and 1.0 mm were
expressed as a percentage of the number of axons observed at
1.5 mm proximal to the injury site. Counts were cumulative from
the five sections with the highest counts. Images of labeled axons
were taken with a Zeiss Axio Imager and AxioVision v4.8
software. Photomontage figures were produced using Adobe
Photoshop 6.0.
Behavioral analyses
The open-field locomotion score was evaluated using the
modified Basso-Beattie-Bresnahan (mBBB) scoring system of
20 points [23]. Ability to walk/climb on a horizontal and angled
grid and grasp strength were performed as previously described
[12]. The data were presented as mean6SEM and intergroup
comparisons analyzed by one-way ANOVA followed by Tukey’s
post comparison analysis. In the case of the mBBB analysis,
repeated measures ANOVA was used to examine improvement
over time within groups.
Kinematic gait analysis
Locomotion of the left hind limb was recorded prior to the
lesion and at 5 weeks after left hemisection, essentially as we
previously described [26]. The left hind limb was shaved and
reflective markers (3 mm hemispherical; B&L Engineering) were
placed over the iliac crest, the femoral head (hip joint), the knee
joint and the ankle joint. The lateral metatarsophalangeal joint
(little toe) was used as the 5
th point. A video camera (Sony HDR-
HC1) operating at 25 frames per second (shutter rate=1/
1250 sec) captured the sagittal plane motion of the mice (left
hand side) while they walked on the treadmill. The camera was
located 1 m from the center of the walkway (center of lens level
with treadmill) with a field of view of approximately 32 cm
(length)624 cm (height). The camera lens was leveled in three
planes (sagittal, frontal and transverse) to minimize perspective
and parallax error.
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reflective markers and the 5
th metatarsophalangeal joint were
digitized directly from the video image using the Peak Motus Motion
Measurement System (Peak Performance Technologies). This system
captures 50 images or fields for each second (sample rate=50 Hz).
The raw spatial coordinate data were filtered (smoothed) using a 4
th
order Butterworth digital filter with a cut-off frequency of 5 Hz. The
kinematics of several full steps was then analyzed for each mouse.
Kinematic data were time-normalized and ensemble averaged across
the animals for each group. Inter-subject average kinematic profiles
were generated by calculating the mean6SEM of the joint angles at
4% intervals over the stride period.
Statistics
All statistics were performed using GraphPad Prism 4.0
software. Analysis of treatment effects was performed using one-
way ANOVA followed by Tukey’s post-hoc test for group
comparisons or unpaired t-tests for individual comparisons, with
significance set at p,0.05.
Supporting Information
Figure S1 Additional examples of anterograde tracing 6
weeks after spinal cord injury. Spinal cords from (a) PBS
control, (b) ephrin-A5-Fc treated and (c) EphA4-Fc treated mice.
Arrows indicate lesion site. (d) Local administration of EphA4-Fc
does not promote axonal regeneration through the lesion.
Immediately following spinal cord injury, 100 mg EphA4-Fc or
human IgG was added in a 10 ml solution to 364 mm gelfoam
and placed directly above the injury site. Local administration of
EphA4-Fc by saturated gelfoam resulted in slightly better axonal
regrowth than the 1-week i.p. treatment, with many axons
entering the lesion site (white arrows), but it was not as effective
as the 2-week i.p. treatment. Scale bars in a-c, 50 mm; d, 200 mm.
(e) Analysis of EphA4-Fc clearance. EphA4-Fc (1 mg) was injected
i.p. and blood samples from three animals were taken at 24 hours,
48 hours and 7 days. One uninjected animal served as a baseline
control. Serum was prepared from the blood samples and
circulating EphA4-Fc was detected by ELISA. Briefly, purified
anti-mouse EphA4 (IF9) monoclonal antibody was bound to EIA
plates. Reference EphA4-Fc was diluted from 200 ng/ml to 0 ng/
ml and the serum was diluted 1:1000 and 1:2000. All standards
and samples were added in triplicate. Following washing, bound
EphA4-Fc was detected with anti-human IgG-HRP and SIGMA-
FAST
TM OPD colorimetric substrate. A 4
th-order polynomial
standard curve was generated (r
2.0.999) and used to calculate the
serum levels of EphA4-Fc. Data are presented as mean6SEM.
(TIF)
Figure S2 Anterograde tracing of spinal cords that were
labeled prior to spinal cord hemisection. Anterograde
tracing of spinal cords at 4 days post-injury, labeled 1 week prior to
injury shows that there was axonal die-back in control and treated
mice. Arrow indicates injury site. Scale bar, 500 mm.
(TIF)
Video S1 Control mice on climbing grid 5 weeks after
spinal cord injury. Mice were assessed for functional recovery,
as determined by the use of their left hind limb, at 5 weeks after
spinal cord hemisection. Control mice were unable to effectively
use their left hindlimb to climb an angled grid.
(WMV)
Video S2 Ephrin-A5-Fc-treated mice 5 on climbing grid
weeks after spinal cord injury. Mice were assessed for
functional recovery, as determined by the use of their left hind
limb, at 5 weeks after spinal cord hemisection. Ephrin-A5-Fc
treated mice were able to use their left hindlimb to climb an angled
grid and bear weight.
(WMV)
Video S3 Control mice on treadmill 5 weeks after spinal
cord injury. Mice were assessed for functional recovery, as
determined by the use of their left hind limb, at 5 weeks after
spinal cord hemisection. Control mice were unable to effectively
use their left hindlimb to walk on a treadmill.
(WMV)
Video S4 Ephrin-A5-Fc-treated mice on treadmill 5
weeks after spinal cord injury. Mice were assessed for
functional recovery, as determined by the use of their left hind
limb, at 5 weeks after spinal cord hemisection. Ephrin-A5-Fc
treated mice were able to use their left hindlimb to walk on a
treadmill, with a step cycle pattern involving use of multiple joints.
(WMV)
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